The Celigo Image Cytometer has been previously used for a wide range of immuno-oncology and immunotherapy studies, demonstrating the great utility of this instrument to assess the activity of cytotoxic immune cells against malignant cells of interest.
Sangivamycin is an unsuccessful anti-cancer drug candidate that has proven to be a potent inhibitor of multiple viruses. The authors of this study hypothesized that this compound would also be active against SARS-CoV-2.
The ongoing pursuit of novel anti-cancer therapeutics must consider the potential for off-target effects on the immune system.
The researchers in this study first utilized various techniques to explore the role of MEX3A in glioma, including immunohistochemistry to assess MEX3A expression levels in glioma tissues, knockdowns of MEX3A in conjunction with a transwell assay to assess migration and an in-vivo mouse model of tumor burden.
The severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused the ongoing COVID-19 pandemic, infecting more than 206 million people and causing upwards of 4.34 million deaths at the time of writing.
Metastatic spreading from solid tumors continues to be one of the greatest challenges facing oncologists and clinicians, often leading to a fatal outcome for many patients.
When screening for novel drugs and accessing drug effectiveness against viruses, automated high-throughput imaging with the Celigo Image Cytometer can have significant advantages in speed, accuracy, and cost over other methods.
Image cytometry for cell counting, proliferation, cell cycle, and other assays for whole-well live-cell analysis and cell sample characterization in brightfield and fluorescence.
Drug repurposing, also known as drug repositioning is a powerful tool for the rapid expansion of available therapy options by identifying new therapeutic uses from pre-existing drugs.